Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
24:489–491 © 2000 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume 24, 2000

Author Index

Abdullah F, 23
Abeli C, 115
Abtahi A, 86
Accetturi CA, 399
Achkar JM, 203
Adams JM, 79
Ades AE, 292
Adorni F, 115
Adult/Adolescent Spectrum of Disease Project Group, 270
Adult/Adolescent Spectrum of HIV Disease Project, 294
AIDS Clinical Trials Group 175 Team, 316p 268 Study Team, 337
Akbari B, 79
Alary M, 425
Albert J, 1
Alessandri G, 465
Ammassari A, 123
Anastos K, 68, 218
Anderson CE, 249
Andrews L, 241
Angarano G, 232
Ansari AA, 10, 89
Antinori A, 123
Antunes F, 257
Aperia K, 1
APROCO Study Group, 82
Arango-Jaramillo S, 197
Armenta-Solis A, 465
Arts EJ, 408
Auewarakul P, 285
Aymard G, 344

Baeten JM, 458
Bagnarelli P, 232
Balotta C, 232
Balsari A, 465
Bandrés JC, 203
Barreiro P, 76, 488
Barré-Sinoussi F, 1
Batista S, 175
Beall G, 386
Beatty P, 289
Becker S, 337
Beilenson P, 57
Belec L, 418
Bélec L, 147
Bergmann J-F, 344
Berlusconi A, 232
Bhatt SM, 23
Bini T, 115
Black JR, 337
Blattner W, 45
Bongiovanni M, 115
Boros S, 84
Bostik P, 89
Bower M, 310
Brice GT, 10, 89
Briones C, 76
Bruneau J, 425
Brun-Vézinet F, 82
Burns D, 68
Burns DN, 45
Bwayo JJ, 458

Canchola J, 363
Carlo DJ, 264
Carosi G, 211
Caruso A, 465
Casari S, 211
Castelnuovo B, 115
Castillo RC, 197
Catania J, 363
Caulin C, 344
Chaix C, 227
Chang S-C, 287, 378
Chantry CJ, 325
Chaouat G, 1
Chaowanachan T, 401
Charles C, 241
Charurat M, 45
Chen M-Y, 287, 378
Chêne G, 82
Chesson HW, 48
Cheung T, 444
Chiesa E, 115
Chirenje ZM, 62
Chokephaibulkit K, 401
Chotpitayasunondh T, 401
Chuachoowong R, 401
Cingolani A, 123
Clark RA, 290
Clementi M, 232
Clevenbergh P, 227
Cloyd M, 352
Cocroft J, 249
Cohen M, 68, 218
Collins KR, 408
Conway B, 425
Cooper ER, 45
Coovadia H, 37
Coovadia HM, 330
Costagliola D, 418
Côté P, 425
Cotton DJ, 316
Coutsoudis A, 37, 330
Currier J, 386
Currier JS, 316
Cu-Uvin S, 68, 297

d'Arminio Monforte A, 115
Dabis F, 178
Daily JP, 129
Dascomb K, 290
Davidson W, 475
De Luca A, 123
de Melo MF, 175
de Souza RS, 154
Dellamonica P, 227
Detels R, 218
DeVellis B, 275
DeVellis R, 275
Diaz C, 325
Diaz RS, 399
Didier E, 290
Diquet B, 344
do Lago RF, 175
Dohn M, 337
Dolcini G, 1
Dona C, 76
Donato F, 211
Duncombe C, 78
Durand-Zaleski I, 227
Durant J, 227
Durol ALiza B, 129
Dworkin MS, 270, 294

Edlin BR, 162
Ekpini E, 257
European Network for In Utero Transmission of HIV-1, 1
Ewings EL, 100

Facchi G, 232
Faulhaber JC, 175
Fenyö EM, 1
Fessel WJ, 194
Finkelstein D, 337
Fiorentini S, 465
Flanigan TP, 297
Fleishman JA, 182
Follansbee SE, 194
Frazer T, 290
Fredriksson R, 1
Friedland G, 241

Galli M, 232
Gallicano K, 123
Gange SJ, 218
García-Lerma G, 257
Garrafa E, 465
Gazzard BG, 310
Georges A, 147
Georges-Courbot M-C, 147
Gerschenson M, 100
Ghezzi A, 211
Giermakowska WK, 264
Gill MJ, 475
Giorgi JV, 218
Githui WA, 23
Goldenberg RL, 369
Gómez-Marín O, 154
González-Lahoz J, 76, 488
Gorbach SL, 137
Gorny MK, 203
Graf JA, 129
Graviss EA, 30
Green TA, 257
Greenberg KP, 89
Greenblatt DJ, 129
Greenblatt R, 68
Greenblatt RM, 218
Grenier-Sennelier C, 227
Grimes J, 316
Gross M, 393
Groupe d'Étude Clinique de l'Infection VIH en Guyane Francaise, 178
Guasti S, 154
Guimarães NC, 175
Gwanzura L, 62

Halvorsen R, 289
Hamill RJ, 30
Hammer SM, 316
Hanson DL, 270
Harbaugh JW, 100
Harbaugh SW, 100
Harlow SD, 68
Harmatz JS, 129
Harrison LH, 175
Hauck WW, 249
Hawken MP, 23
Heagerty P, 451
Hellinger FJ, 182
Heneine W, 257
Hepatitis-HIV Study Group, 211
Hewitt RG, 79
Hillyer G, 325
Hoff R, 45
Hoffman JL, 129
Holte S, 451
Holte SE, 393
Hsieh S-M, 287, 378
Huettner S, 57
Hughes MD, 316
Hung C-C, 287, 378

Iliff V, 62
Imberti L, 465
Ippolito G, 440

Jacobson D, 123
Jaffe D, 363
Jaffe HW, 270
Jatlow P, 241
Jensen FC, 264
John R, 197
Johnson D, 386
Jones JL, 270
Jordan W, 386

Katz MH, 168
Katzenstein DA, 316
Kazatchkine MD, 418
Kennedy CM, 37
Kerndt PR, 386
Kirschner D, 352
Kissinger P, 290
Kitahata MM, 106
Klein RS, 68
Knox TA, 137
Koblin BA, 393, 451
Kovacs A, 218
Kozlowski PA, 297
Kral AH, 162
Kreiss JK, 458
Kuhn L, 37, 330

Lacke CE, 30
Landesman S, 218
Lau B, 218
Lavreys L, 458
Le Beux P, 178
Le Moing V, 82
LeBlanc R, 425
Ledeine JM, 418
Lee T-H, 285
Lefèbvre E, 425
Lenderking B, 451
Levine A, 218
Levine AM, 444
Lewi DS, 399
Lewis MG, 89
Li P, 444
Licenziati S, 465
Lin X, 68
Lippi M, 232
Lorvick J, 162
Lu P-L, 287
Lu S, 386
Lucas SB, 23
Lynch RM, 297

Machuca A, 189
MacKellar D, 168, 363
Makuva M, 147
Mandalia S, 310
Mandaliya K, 458
Manshino K, 257
Margolick JB, 218
Marmor M, 393
Martin HL Jr, 458
Marx MA, 57
Mason PR, 62
Masquelier B, 82
Mastro TD, 401
Matta M, 147
Matthews GV, 310
Mayanja-Kizza H, 408
Mayer KH, 393
Mayne AE, 10, 89
Mbizvo MT, 62
Mburu A, 37
McCance-Katz EF, 241
McCune J, 289
McFarland W, 168
Melnick S, 218
Melzi S, 115
Menu E, 1
Mertzanis P, 129
Minkoff H, 68
Mitchell CD, 154
Mitchell SM, 241
Mock PA, 401
Mocroft A, 475
Mohammed AS, 418
Monno L, 232
Montaner JSG, 433
Moreira RI, 175
Morelli A, 147
Moroni M, 232
Morrison P, 325
Morse GD, 79
Moss RB, 264
Mouly S, 344
Moyle GJ, 310
Muderspach L, 68
Mueller N, 86
Muñoz A, 218
Murri R, 123
Mwachari C, 23
Mwatha A, 393

Nagashima K, 100
Nathwani BN, 444
Ndinya-Achola JO, 458
Nelson M, 310
Neutra MR, 297
Newschaffer CJ, 249

Ng'ang'a LW, 23
Ngugi EN, 458
Nkengasong JN, 257
Novaes Pinto GH, 399
Nyambi P, 203
Nyange PM, 458

O'Sullivan MJ, 154
Ohmit SE, 68
Okayama A, 86
Oliveira RH, 154
Oller V, 488
Osmond DH, 363

Padian NS, 62
Panchula J, 325
Para MF, 337
Pardini R, 399
Parker S, 292
Pattanapanyasat K, 285
Patterson RR, 297
Peter JB, 83
Pezzotti P, 84
Phair J, 218
Phillips AN, 475
Pillay K, 37, 330
Pinkerton SD, 48
Poirier MC, 100
Pollack L, 363
Porter JDH, 23
Power C, 23
Projeto Praça Onze Study Group, 175
Puoti M, 211
Puro V, 440
Putzolu V, 211

Quinn SC, 275
Quiñones-Mateu ME, 408
Quiros-Roldan E, 211

Raboud JM, 433
Rae S, 433
Raffi F, 82
Rainey PM, 241
Rana FS, 23
Ratner L, 444
Reynes J, 82
Rezza G, 84
Richardson BA, 458
Ricotta D, 465
Riley ED, 57
Rinaldo CR, 218
Riva C, 232
Rivera C, 325
Roenn JV, 444
Rompalo A, 68
Roubenoff R, 137
Rouleau D, 425
Rouse DJ, 369
Routy J-P, 425
Rusconi S, 232

Safaeian M, 57, 483
Sangsiriwut K, 285
Sassan-Morokro M, 257
Savary JR, 264
Schapiro JM, 227
Schechter M, 175
Schlegel P, 289
Schuman P, 68
Schwartz DH, 197
Scott GB, 154
Sekaly R-P, 425
Sengupta S, 275
Serraino D, 84
Shader RI, 129
Shaffer N, 401
Shanmugam V, 257
Shelton MJ, 79
Sheng W-H, 378
Sheppard HW, 175
Shiboski S, 62
Shields AW, 106
Sicard D, 82
Signorini S, 465
Simonds RJ, 401
Sinkala M, 369
Skopets B, 100
Sobesky M, 178
Sollima S, 115
Soriano V, 76, 189, 257, 488
Spiegelman D, 137
Spindel SA, 30
Spinetti A, 211
Spino C, 316
StClaire MC, 100
Stein Z, 37
Stinnett AA, 369
Strathdee SA, 57
Strauss RP, 275
Stringer JSA, 369
Stuver S, 86
Sullivan BA, 408
Switzer WM, 257

Taylor E, 483
Testa L, 115
Tévi-Bénissan C, 147
Thomas DL, 483
Toossi Z, 408
Troccaz M, 418
Tscherning-Casper C, 1
Tsoukas C, 425
Tulpule A, 444
Turano A, 465
Turcato G Jr, 399
Turner BC, 197
Turner BJ, 249

Valleroy L, 363
Valleroy LA, 168
van de Wijgert JHHM, 62
Van PN, 418
Van Rompaey SE, 106
Vanden Heuvel EA, 30
Vanhems P, 425
Vanparapar N, 401
Vermund SH, 369
Villinger F, 10, 89
Violin M, 232
Vlahov D, 57, 483
Vödrös D, 1
von Moltke LL, 129

Walawander A, 337
Waldo CR, 168
Walker J, 292
Wallace MR, 264
Wan Pei-Chun T, 294
Wang X-H, 203
Waranawat N, 401
Ware WB, 275
Warren D, 68
Wasi C, 285
Wasinrapee P, 401
Webb E, 264
Webb GF, 352
Weber JN, 292
Weiser B, 218
White AC Jr, 30
Wiktor SZ, 257
Wilson IB, 137
Wilson LE, 483
Wofsy CB, 316
Wohl AR, 386
Wu AW, 123

York D, 330
Young M, 218
Young MA, 68
Young NL, 401
Young TP, 194

Zaltron S, 211
Zanini B, 211
Zimmerman E, 197
Zolla-Pazner S, 203
Zorilla C, 325

JAIDS Journal of Acquired Immune Deficiency Syndromes
24:492–498 © 2000 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology Volume 24, 2000

Subject Index

ABVD chemotherapy, in HIV-infected patients with newly diagnosed Hodgkin's disease, 444
Adherence
  in prophylaxis for vertical HIV transmission, 369
  protease inhibitor levels and, 123
Adverse drug reactions, in once-daily regimen of antiretroviral combination therapy (letter), 287
Africa
  autopsy study of HIV-1 patients in, 23
  cell-free virus in breast milk of HIV-1-seropositive women of, 330
  coreceptor usage of HIV-1 isolates from pregnant women in, 1
  HIV-1 incidence among prostitutes in, 458
  intravaginal practices and vaginal and cervical mucosa of women in, 62
  nevirapine to prevent vertical HIV transmission in, 369
African-Americans
  factors affecting participation of in AIDS research, 275
  male, high-risk behavior among during incarceration, 386
AIDS
  clinical spectrum, morbidity and mortality of in Taiwan, 378
  clinical trials for *Pneumocystis carinii* pneumonia prophylaxis in, 337
AIDS-defining cancers, antiretroviral combination therapies and (letter), 84
AIDS research, factors affecting African-American participation in, 275
Alcohol-related liver disease, mortality with in HIV-infected patients, 211
Allogeneic bone marrow transplant, in HIV-1-positive man with chronic myelogenous leukemia (letter), 289
Amenorrhea, HIV infection effect on, 68
Amp-RT activity, in HIV-1 and HIV-2, 257
Anal sex, among HIV-seronegative women at high risk of HIV exposure, 393
Antibody-mediated HIV-1 neutralization, polymerase chain reaction assay for, 203
Antiretroviral drugs
  adverse drug reactions, tolerability, and efficacy of once-daily regimen of (letter), 287
  effect of on T-lymphocyte subset counts in healthy HIV-negative individuals, 440
  failure of in HIV-1 infected Italian patients, 232
  predicting HIV RNA virologic outcome at 52-week follow-up in clinical trials of, 433
  surveillance of prescriptions (letter), 294
Antiretroviral therapy
  CCR5 polymorphism effects in (letter), 399
  combination
    AIDS-defining cancers and (letter), 84
  didanosine dosage in double or triple combination regimens, 418
  early adoption of, 106
  gender differences in starting, 475
  HTLV proviral load fluctuations with, 189
  Kaposi's sarcoma incidence and trends in, 270
  lipolysis and heat treatment of breast milk in, 325
  mother-infant HIV transmission and trends in, 45
  second-line protease inhibitor outcomes in patients intolerant of, 115
  virologic response definition and assay type influencing proportion of responders to (letter), 82
Antiviral drugs, HIV-1-specific CD4 helper function after, 264
Apoptosis, homing-induced, of $CD4^+$ lymphocytes, 352
Assays, in quantification of viral load (letter), 82
Autopsy, of HIV-1-positive and -negative patients in Kenya, 23

Bacterial infections, among injection drug users, 483
Benzalkonium chloride, in protection of cynomolgus macaque against SIVmac251 transmission, 147
Birth defects, with prenatal zidovudine use, 249
Bisexual men, at risk for HIV infection in, 168
Bleomycin, in HIV-infected patients with newly diagnosed Hodgkin's disease, 444
Body composition, health status and, 137
Bone marrow transplant, allogeneic, in HIV-1-positive man with chronic myelogenous leukemia (letter), 289
Bonzo/CCR5 coreceptors, during pregnancy, 1
Brain, transplacental zidovudine exposure and genotoxic effects on, 100
Brazil
  CCR5 polymorphism and HIV-1 subtype effects in antiretroviral response in (letter), 399
  identifying high-risk heterosexual population for HIV prevention trials in, 175
Breast milk
  cell-free virus in HIV-1-seropositive women, 330
  lipolysis and heat treatment effects on HIV-1 provirus in, 325

Cameroon, coreceptor usage of HIV-1 isolates from pregnant women in, 1
Cancer, AIDS-defining, antiretroviral combination therapies and (letter), 84

Caribbean, HIV/AIDS epidemic in, 178
CCR5
  age-dependent expression of (letter), 285
  coreceptor, HIV-1 isolates and, 1*CCR5* polymorphism, effects of in antiretroviral response in Brazilian HIV-1-infected patients (letter), 399
$CD4^+$ T-cell count
  antiretroviral effects on in healthy HIV-negative individuals, 440
  race and gender association with in HIV-1 RNA levels and immunologic progression, 218
$CD4^+$ T-cells
  age-dependent expression of HIV-1 coreceptor CCR5 on (letter), 285
  expansion of with impaired effector functions in HIV-1-infected patients, 465
  lymph node homing and homing-induced apoptosis of, 352
  mode of activation of, 10
  response of to nucleoside analogues, 316
  telomerase activity/proliferation of and disease progression in SIV-infected nonhuman primates, 89
CD8 T-cells, expansion of with impaired effector functions in HIV-1-infected patients, 465
CD28 T-cells, expansion of with impaired effector functions in HIV-1-infected patients, 465
CD4 T helper function, HIV-1-specific, measurement of after antiviral drug therapy, 264
CD11b T-cells, expansion of with impaired effector functions in HIV-1-infected patients, 465
Cell-free virus, in breast milk of HIV-1-seropositive women, 330
Cervical cancer, antiretroviral combination therapies and (letter), 84
Cervical mucosa, intravaginal practices and, 62
Cervicovaginal transmission, protection of cynomolgus macaque against, 147
Chemokines, in regulating $CD4^+$ T cell disease susceptibility, 10
Chemotherapy, in HIV-infected patients with newly diagnosed Hodgkin's disease, 444
Children, age-dependent expression of HIV-1 coreceptor CCR5 on $CD4^+$ cells in (letter), 285
Clinical prediction model, for differentiation of disseminated *Histoplasma capsulatum* and *Mycobacterium avium* complex infections in febrile AIDS patients, 30
Clinical trials, predicting HIV RNA virologic outcome at 52-week follow-up in, 433
Cohort study, of mortality for liver disease in HIV-infected patients, 211
Colposcopy, effect of on cervical and vaginal mucosa of Zimbabwean women, 62
Combination antiretroviral therapy
  adverse drug reactions, tolerability, and efficacy of once-daily regimen of (letter), 287
  AIDS-defining cancers and (letter), 84
  didanosine dosage in, 418
Community telephone survey, obtaining HIV test results with home collection test kit in, 363
Condom use, with anal sex among HIV-seronegative women, 393
Congenital anomalies, with prenatal zidovudine use, 249
Coreceptor usage
  of HIV-1 isolates, 1
  tumor necrosis factor-α regulating $CD4^+$ T cell susceptibility for, 10
Cost, of HIV treatment, 182
Cost-effectiveness analysis
  of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa, 369
  of sexually transmitted disease prevention interventions, 48
Cytochrome P450-3A, inhibiting and inducing activity of, 129
Cytokines, in regulating $CD4^+$ T cell disease susceptibility, 10
Cytotoxic T lymphocytes, expansion of with impaired effector functions in HIV-1-infected patients, 465

Dacarbazine, in HIV-infected patients with newly diagnosed Hodgkin's disease, 444
Delavirdine, in eradication of *Helicobacter pylori* (letter), 79
Developing countries, lipolysis and heat treatment of breast milk in, 325
Diagnostic tests, for early detection in HIV-1-infected infants in Thailand, 401
Diarrhea, enhanced oral ganciclovir systemic exposure with, 344
Didanosine
  dosage of for patients on double or triple combination antiretroviral therapy, 418
  interaction with methadone, 241
Disease progression
  based on virus-induced lymph node homing and homing-induced apoptosis of $CD4^+$ lymphocytes, 352
  gender differences in, 475
  inverse correlation of telomerase activity/proliferation of $CD4^+$ T cells and, 89
  prenatal zidovudine effect on, 154
Distrust, in African-American participation in AIDS research, 275
DNA, HIV-1 proviral, lipolysis and heat treatment effects on in breast milk, 325
DNA polymerase chain reaction, for early diagnosis in HIV-1-infected infants in Thailand, 401
Dosing, once- and twice-daily in combination antiretroviral therapy, 418
Doxorubicin, in HIV-infected patients with newly diagnosed Hodgkin's disease, 444
Drug efficacy, in once-daily regimen of antiretroviral combination therapy (letter), 287
Drug interactions
  of methadone with didanosine and stavudine, 241
  of protease inhibitors, 129
Drug monitoring, protease inhibitor levels and, 123
Drug reactions
  to nucleoside analogues, 316
  in once-daily regimen of antiretroviral combination therapy (letter), 287
  to trimethoprim-sulfamethoxazole prophylaxis, 337
Drug-related risk, in injection drug users in San Francisco, 162
Drug resistance genotyping, economic evaluation of, 227
Drug tolerability, in once-daily regimen of antiretroviral combination therapy (letter), 287
Drug use
  among incarcerated African-American men, 386
  in very young gay and bisexual men, 168

Economic evaluation, of drug resistance genotyping for adaptation of HIV treatment, 227
Efavirenz, in rescue of early failure with nevirapine (letter), 76
Effector functions, CD T cell expansion with impairment of, 465
ELISPOT, measuring HIV-1-specific CD4 helper function with antiviral drug therapy, 264
Endocarditis, in injection drug users, 483
Enzyme-linked immunoassay, for HIV seroprevalence testing, 363
Epidemiology
of HIV-1 and HIV-2, 257
of HIV in African-American incarcerated population, 386
of HIV infection in injection drug users, 162
Erratum: "Evaluation of a statewide non-name-based HIV surveillance system" (22;3: pages 272-279), 296
Ethnicity, in unlinked anonymous neonatal HIV seroprevalence surveys (letter), 292

Febrile patients, disseminated *Histoplasma capsulatum* and *Mycobacterium avium* complex infections in, 30
French Guiana, HIV/AIDS epidemic in, 178

Ganciclovir, systemic exposure enhanced in HIV-infected patients with diarrhea and weight loss, 344
Gay men, at risk for HIV infection in, 168
Gender differences
in adverse events and $CD4^+$ responses to nucleoside analogues, 316
in HIV-1 RNA levels and immunologic progression, 218
in starting protease inhibitors, HAART, and disease progression, 475
Genetic subtypes, coreceptor usage of HIV-1 isolates representing, 1
Genital herpes, prevention of to reduce HIV transmission risk, 48
Genotyping, in HIV treatment adaptation, 227
Gonorrhea, prevention of to reduce HIV transmission risk, 48
gp120-depleted immunogen, inactivated, ELISPOT after treatment with, 264
Granulocyte-colony-stimulating factor, in HIV-infected patients with newly diagnosed Hodgkin's disease, 444

HAART
adverse drug reactions, tolerability, and efficacy of once-daily regimen of (letter), 287
in clinical spectrum, mobidity and mortality of AIDS in Taiwan, 378
development of in vitro resistance to macrophage-tropic and T-cell-line-adapted HIV-1 strains with, 197
gender differences in starting, 475
in HIV-infected patients with newly diagnosed Hodgkin's disease, 444
patient-reported nonadherence to and protease inhibitor levels, 123
salvage therapy and formulation of (letter), 194
second-line protease inhibitors for patients failing, 115
Health-related quality of life, lean body mass and, 137
Heat treatment, effects of on HIV-1 provirus in breast milk, 325
Helicobacter pylori, eradication of with increased exposure to delavirdine in hypochlorhydric HIV-positive patients (letter), 79
Hepatitis B virus, mortality with in HIV-infected patients, 211
Hepatitis C virus, mortality with in HIV-infected patients, 211
Hepatitis D virus, mortality with in HIV-infected patients, 211
Herpes simplex virus, prevention of to reduce HIV transmission risk, 48
Heterogeneity, of HIV-1 quasispecies in HIV-infected individuals with active tuberculosis, 408
Heterosexual men, high-risk behavior among during incarceration, 386
Heterosexual population, identifying high-risk for HIV in, 175
High-risk populations
in HIV prevention trials in Brazil, 175
willingness and knowledge among, 451
Histoplasmosis, disseminated, clinical prediction model for, 30
HIV-1 coreceptors, age-dependent expression of (letter), 285
HIV-1 immunogen, ELISPOT after treatment with, 264
HIV-1 infection
allogeneic bone marrow transplant in (letter), 289
autopsy study of in Kenya, 23
clinical features of in patients infected sexually or through injection drug use, 425
disease progression model based on virus-induced lymph node homing and homing-induced apoptosis of $CD4^+$ lymphocytes, 352
incidence of among prostitutes in Kenya, 458
lower plasma viral load and natural history of, 257
multiple dideoxynucleoside analogue-resistant variants of, 232
perinatal infection of, 154
HIV-2 infection, lower plasma viral load and natural history of, 257
HIV-1 isolates, coreceptor usage of, 1
HIV-1 neutralization, antibody-mediated, polymerase chain reaction assay for, 203
HIV-1 provirus, lipolysis and heat treatment effects of in breast milk, 325
HIV-1 quasispecies, diversity of with active tuberculosis, 408
HIV-1 RNA, race and gender associated with, 218
HIV-1 strains, in vitro resistance to, 197
HIV-1 subtypes
effects of in antiretroviral response in Brazilian HIV-1-infected patients (letter), 399
subtype A, mother-child transmission of, 1
HIV-1 vaccine efficacy trials, among prostitutes in Kenya, 458
HIV/AIDS epidemic, in French Guiana, 178
HIV antibody
polymerase chain reaction assay for, 203
in rectal secretions, 297
HIV diagnostic tests, for early detection in HIV-1-infected infants in Thailand, 401
HIV infection
clinical prediction model for disseminated infections in, 30
intravaginal practices and, 62
lean body mass and health-related quality of life in, 137

in menstrual cycle length, 68
morbidity and mortality of in Taiwan, 378
mortality for liver disease with, 211
physician experience in caring for and early adoption of new antiretroviral therapy for, 106
sex- and drug-related risk behavior among injection drug users and, 162
young gay and bisexual men at risk for, 168
HIV network, high-risk populations in, 451
HIV-positive patients, delavirdine in eradication of *Helicobacter pylori* in (letter), 79
HIV prevention
mobile versus pharmacy-based needle exchange programs in, 57
trials identifying high-risk heterosexual population for, 175
HIV RNA virologic outcome, prediction of at 52-week follow-up, 433
HIV seroprevalence, home collection test kit for, 363
HIV subtypes, early diagnosis of in HIV-1-infected infants in Thailand, 401
HIV testing, in prophylaxis for vertical HIV transmission, 369
HIV transmission
increased risk of with sexually transmitted disease, 48
mother-infant, antiretroviral therapy trends and, 45
HIV vaccine trials, readiness for, 451
HIV viral loads, high, low, and very low (letter), 83
Hodgkin's disease, ABVD chemotherapy with granulocyte-colony-stimulating factor with, 444
Home collection test kit, HIV test results with, 363
Homeless, sex- and drug-related risk behavior among, 162
Homing-induced apoptosis, of $CD4^+$ lymphocytes, 352
Homosexual men
high-risk behavior among during incarceration, 386
readiness for HIV vaccine trials in, 451
Hospital-based surveillance system, of HIV/AIDS patients, 178
HTLV-I-associated myelopathy/tropical spastic paraparesis, HTLV-I in subclinical infection of (letter), 86
HTLV-I infection
proviral load fluctuations with antiretroviral drugs, 189
in subclinical HAM/TSP in Miyazaki cohort study (letter), 86
HTLV-II infection
among injection drug users, 483
proviral load fluctuations with antiretroviral drugs, 189
Hyperlipidemia, reversal of in patients switching to nelfinavir (letter), 78

IgG subclasses, in rectal secretions, 297
Immune reconstitution, with in vitro resistance to macrophage-tropic and T-cell-line-adapted HIV-1 strains in HAART-treated volunteers, 197
Immunologic progression, race and gender associated with, 218
Indinavir, potent activity but limited tolerance of (letter), 488
Infants
early diagnosis of HIV-1 infection among in Thailand, 401
prenatal zidovudine and disease progression in, 154
Injection drug users
clinical features of acute HIV-1 infection in, 425
HIV risk and among very young gay and bisexual men, 168
HTLV-II and bacterial infections among, 483
mobile versus pharmacy-based needle exchange programs for, 57
readiness for HIV vaccine trials in, 451
sex- and drug-related risk behavior among, 162
Interferon-γ, ELISPOT after treatment with, 264
Intestinal absorption, of oral ganciclovir with diarrhea and weight loss, 344
Intolerance, second-line protease inhibitor outcomes and, 115
Intravaginal practices, effect of on vaginal and cervical mucosa in Zimbabwean women, 62
In vitro metabolism, of protease inhibitors, 129
In vitro resistance, to macrophage-tropic and T-cell-line-adapted HIV-1 strains among HIV-positive volunteers treated with HAART, 197
Italy, multiple dideoxynucleoside analogue resistance in multicenter cohort of HIV-1-infected patients in, 232

Kaposi's sarcoma
antiretroviral combination therapies and (letter), 84
incidence and trends in with effective antiretroviral therapy, 270
Kenya
autopsy study of HIV-1 patients in, 23
HIV-1 incidence among prostitutes in, 458

Lean body mass, health-related quality of life and, 137
Lentiviruses, in regulating $CD4^+$ T-cell susceptibility for coreceptors, 10
Letters to editor
age-dependent expression of the HIV-1 coreceptor CCR5 on $CD4^+$ lymphocytes in children, 285
antiretroviral combination therapies and AIDS-defining cancers, 84
can early failure with nevirapine be rescued with efavirenz?, 76
definition of virologic response and the type of assay used for quantification of viral load may influence the proportion of responders to antiretroviral therapy, 82
effects of *CCR5* genetic polymorphism and HIV-1 subtype in antiretroviral response in Brazilian HIV-1-infected patients, 399
eradication of *Helicobacter pylori* is associated with increased exposure to delaviridine in hypochlorhydric HIV-positive patients, 79
high, low, and very low viral loads of HIV in the United States, 83
lack of evidence for a role of HTLV-I infection in the occurrence of subclinical HAM/TSP in the Miyazaki cohort study, 86
microsporidiosis and HIV, 290
potent activity but limited tolerance of ritonavir plus indinavir in salvage interventions, 488
preliminary experience of adverse drug reactions, tolerability, and efficacy of a once-daily regimen of antiretroviral combination therapy, 287
reversal of hyperlipidemia and lipodystrophy in patients switching therapy to nelfinavir, 78

salvage therapy and formulation of highly active antiretroviral therapy, 194
serotype, parental country of birth, and ethnic status in unlinked anonymous neonatal HIV seroprevalence surveys, 292
successful allogeneic bone marrow transplant in an HIV-1-positive man with chronic myelogenous leukemia, 289
surveillance of antiretroviral prescriptions, 294
Leukemia, chronic myelogenous, allogeneic bone marrow transplant in HIV-1-positive man (letter), 289
Lipid abnormalities, thymidine and nonnucleoside analogues and, 310
Lipodystrophy, reversal of in patients switching to nelfinavir (letter), 78
Lipolysis, effects of on HIV-1 provirus in breast milk, 325
Liver disease, mortality for in HIV-infected patients, 211
Los Angeles public medical centers, African-American men treated for HIV at, 386
Lymph node homing, disease progression based on HIV virus-induced, 352
Lymphoblast development, in HIV-1-infected patients, 465
Lymphocytes, lymph node homing and homing-induced apoptosis of, 352
Lymphoma, non-Hodgkin's, antiretroviral combination therapies and (letter), 84

Macrophage-tropic HIV-1 strains, in vitro resistance to, 197
Medicaid population, congenital anomalies with prenatal zidovudine use in, 249
Menstrual cycle, HIV infection effect on length of, 68
Menstruation disorders, HIV infection effect on, 68
Methadone, interaction with didanosine and stavudine, 241
Microsporidiosis, HIV infection and (letter), 290
Mitochondria, zidovudine genotoxic and functional consequences in, 100
Miyazaki cohort study, HTLV-I in subclinical HAM/TSP in (letter), 86
Monkeys, transplacental zidovudine exposure in, 100
Monoclonal antibodies, HIV-1 neutralization by, 203
Mononucleosis syndrome, in acute HIV-1 infection, 425
Morbidity
with AIDS in Taiwan, 378
vitamin A effects on during pregnancy and postpartum in HIV-infected women, 37
Mortality
with AIDS in Taiwan, 378
from HIV-1 in Kenya, 23
for liver disease in HIV patients, 211
Mother-child transmission, HIV-1 subtypes, 1
Mother-infant transmission, antiretroviral therapy and, 45
Mucosal HIV antibody, collecting secretions and analysis of, 297
Multi-institutional AIDS clinical trials group study, of ABVD chemotherapy with granulocyte-colony-stimulating factor, 444
Multiple dideoxynucleodside analogue resistance, prevalence of in multicenter cohort of HIV-1-infected Italian patients with virologic failure, 232
Multitropism, in mother-child HIV transmission, 1
Mycobacterium avium complex infection, clinical prediction model for, 30

Natural history
of HIV-1 and HIV-2, 257
of HIV/AIDS infection, 178
Needle exchange programs, mobile versus pharmacy-based, 57
Nelfinavir, in reversal of hyperlipidemia and lipodystrophy (letter), 78
Neonatal HIV seroprevalence surveys, serotype, parental country of birth, and ethnic status in (letter), 292
Neutralization, antibody-mediated, polymerase chain reaction-based assay for, 203
Nevirapine
cost-effective use of to prevent vertical HIV transmission in sub-Saharan Africa, 369
early failure of (letter), 76
Nonadherence, protease inhibitor levels and, 123
Nonnucleoside analogues, lipid abnormalities in HIV-1-infected persons on, 310
Nonnucleoside reverse transcriptase inhibitors
early adoption and clinical outcomes of, 106
resistant HIV-1 variants and, 232
Nucleoside analogues
gender differences in adverse events and $CD4^+$ responses to, 316
transplacental exposure of in fetal monkey brain mitochondria, 100

Opportunistic infections, HIV-related in Taiwan, 378
Oral HIV testing, home collection test kit for, 363
Outcomes
assessment of with early adoption of new antiretroviral therapy, 106
predicting at 52-week follow-up in antiretroviral clinical trials, 433

p24 assays, nonneutralized viruses undetected by, 203
Parental country of birth, in unlinked anonymous neonatal HIV seroprevalence surveys (letter), 292
Patient-based cost estimates, of HIV treatment, 182
Payer-based cost estimates, of HIV treatment, 182
Perforin expression, in HIV-1-infected patients, 465
Perinatal HIV-1 diagnosis, in HIV-1-infected infants in Thailand, 401
Perinatal transmission
disease progression and zidovudine effects in, 154
nevirapine to prevent in sub-Saharan Africa, 369
Pharmacokinetics
of methadone interacting with didanosine and stavudine, 241
of oral ganciclovir with diarrhea and weight loss, 344
Physician practice patterns, early adoption of new antiretroviral therapy in, 106
Plasma levels, of protease inhibitors, 123
Pneumocystis carinii pneumonia
antiretroviral combination therapies and (letter), 84
reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole prophylaxis for, 337
Pneumonia, bacterial, in injection drug users, 483
Polymerase chain reaction assay
for antibody-mediated neutralization of HIV-1, 203

in early diagnosis of HIV-1-infected infants in Thailand, 401
Population-based sampling, home collection test kit for, 363
Pregnancy
HIV-1 isolates from women during, 1
vitamin A effects on maternal morbidity during in HIV-infected women, 37
Prematurity, HIV-1 disease progression and, 154
Prevention
of HIV infection among risk-taking women, 393
lipolysis and heat treatment of breast milk in, 325
mobile versus pharmacy-based needle exchange programs in, 57
for sexually transmitted disease, 48
trials for
identifying high-risk heterosexual population for, 175
willingness and knowledge among high-risk populations in, 451
Primary care physicians, early adoption of new antiretroviral therapy by, 106
Prison population, high-risk behavior among, 386
Prophylaxis
postexposure, antiretroviral agent effects on T-cell subset counts in, 440
with trimethoprim-sulfamethoxazole in *Pneumocystis carinii* pneumonia, 337
Prostitutes, HIV-1 vaccine efficacy trials among, 458
Protease inhibitors
differential impairment of clearance of, 129
early adoption and clinical outcomes of, 106
gender differences in starting, 475
in mother-infant HIV transmission, 45
patient-reported nonadherence to HAART and levels of, 123
second-line, outcome of in patients failing or intolerant of first HAART, 115
Provider data, in estimating national treatment cost, 182
Proviral load, HTLV, fluctuations of with antiretroviral drugs, 189
Provirus, HIV-1, lipolysis and heat treatment effects on, 325
Psychosocial factors, in very young gay and bisexual men, 168

Q151M mutation complex, in HIV-1-infected patients with virologic failure, 232
Quality of life, lean body mass and, 137

Race, associated with HIV-1 RNA levels and immunologic progression, 218
Randomized controlled trials, for vitamin A effect on maternal morbidity in HIV-infected women, 37
Rectal secretions, modified wick method of collecting, 297
Remune, ELISPOT after treatment with, 264
Research participation, factors affecting in African-Americans, 275
Retroviruses, early diagnosis of in HIV-1-infected infants in Thailand, 401
Reverse transcriptase activity, in HIV-1 and HIV-2, 257
Risk behaviors
in incarcerated African-American men, 386
in injection drug users in San Francisco, 162
of very young gay and bisexual men, 168
Risk factors
for HIV infection, 393
in injection drug users, 483
Ritonavir
differential impairment of clearance of triazolam and zolpidem by, 129
potent activity but limited tolerance of (letter), 488
RNA polymerase chain reaction, for early diagnosis in HIV-1-infected infants in Thailand, 401
RNA virologic outcome, in antiretroviral clinical trials, 433
RT 69 insert, nucleoside reverse transcriptase inhibitors and, 232

Salvage therapy
HAART formulation and (letter), 194
potent activity but limited tolerance of ritonavir plus indinavir in (letter), 488
San Francisco
sex- and drug-related risk behavior among injection drug users in, 162
young men's survey in, 168
Secretory IgA, modified wick method of collecting, 297
Self-reported nonadherence, protease inhibitor levels and, 123
Seroconversion
clinical features of acute HIV-1 infection and, 425
in high-risk heterosexual population, 175
Seroprevalence surveys, serotype, parental country of birth, and ethnic status in (letter), 292
Serotype, in unlinked anonymous neonatal HIV seroprevalence surveys (letter), 292
Sex-related risk, in injection drug users in San Francisco, 162
Sexual behaviors
among high-risk women, 393
HIV-1 incidence trends and, 458
in incarcerated African-American men, 386
of very young gay and bisexual men, 168
Sexual transmission, clinical features of acute HIV-1 infection with, 425
Sexually transmitted diseases
among prostitutes in Kenya, 458
increased HIV transmission risk and, 48
intravaginal practices and, 62
in very young gay and bisexual men, 168
Simian immunodeficiency virus (SIV), inverse correlation of telomerase activity/proliferation of $CD4^+$ T cells and disease progression of, 89
SIVmac251 transmission, protection of cynomolgus macaque against, 147
Skin abscess, in injection drug users, 483
South America, *CCR5* polymorphism and HIV-1 subtype effects in antiretroviral response in (letter), 399
Southeast Asia
clinical spectrum, mobidity and mortality of AIDS in, 378
early diagnosis of HIV-1-infected infants in, 401
Spermicide, in protection of cynomolgus macaque against SIVmac251 transmission, 147
Stavudine, interaction with methadone, 241

Sub-Saharan Africa, nevirapine to prevent vertical HIV transmission in, 369
Substance abuse, mobile versus pharmacy-based needle exchange programs and, 57
Survival rates
  gender differences in, 475
  in HIV/AIDS patients in French Guiana, 178
Syphilis, prevention of to reduce HIV transmission risk, 48
Syringe exchange programs, mobile versus pharmacy-based, 57

T-cell-line-adapted HIV-1 strains, in vitro resistance to, 197
T-cells
  expansion of with impaired effector functions in HIV-1-infected patients, 465
  proliferation of and disease progression of SIV infection, 89
  subset counts of, antiretroviral effects on in healthy HIV-negative individuals, 440
Taiwan, clinical spectrum, mobidity and mortality of AIDS in, 378
Telephone survey, for HIV seroprevalence, 363
Telomerase, inverse correlation of activity and disease progression in SIV-infected nonhuman primates, 89
Thailand, early diagnosis of HIV-1-infected infants in, 401
Thymidine analogues, lipid abnormalities in HIV-1-infected persons on, 310
Transmission
  mother-child, 1
  mother-infant, antiretroviral therapy for, 45
  sexual, 425
  timing of, 154
  vertical (*See* Vertical transmission)
Transplacental drug exposure, genotoxic and functional consequences of, 100
Treatment
  cost estimates of for HIV disease, 182
  failure of in HIV-1 infected Italian patients, 232
Triazolam, differential impairment of clearance, 129
Trimethoprim-sulfamethoxazole, reduced toxicity with gradual initiation of for *Pneumocystis carinii* pneumonia prophylaxis, 337
TSP/HAM patients, proviral load fluctuations in with antiretroviral drugs, 189
Tuberculosis
  in HIV-1 patients in Kenya, 23
  HIV-1 quasispecies diversity with, 408
Tumor necrosis factor-α in regulating $CD4^+$ T cell disease susceptibility, 10

United States, high, low, and very low viral loads of HIV in (letter), 83

Vaccines
  efficacy of among prostitutes kin Kenya, 458
  readiness for trials of, 451
Vaginal microbicide, in protection of cynomolgus macaque against SIVmac251 transmission, 147
Vaginal mucosa, intravaginal practices and, 62
Vertical transmission
  antiretroviral therapy and, 45
  early diagnosis of in Thailand, 401
  in fetal monkey brain, 100
  lipolysis and heat treatment of breast milk in prevention of, 325
  nevirapine to prevent in sub-Saharan Africa, 369
  through breast milk of HIV-1-seropositive women, 330
Vinblastine, in HIV-infected patients with newly diagnosed Hodgkin's disease, 444
VIRADAPT Study, of drug resistance genotyping for HIV treatment adaptation, 227
Viral loads
  in breast milk of HIV-1-seropositive women, 330
  definition of virologic response and type of assay used for quantifying (letter), 82
  high, low, and very low (letter), 83
  of HIV-1 and HIV-2, 257
  in HIV-1-infected infants in Thailand, 401
  prediction of at 52-week follow-up, 433
  race and gender association with in HIV-1 RNA levels, 218
Viral protease inhibitors, differential impairment of clearance of, 129
Virologic failure
  multiple dideoxynucleoside analogue resistance prevalence in, 232
  second-line protease inhibitor outcomes and, 115
Virologic outcome, in antiretroviral clinical trials, 433
Virologic responders, virologic response definition and assay type influencing proportion of (letter), 82
Virologic response, in quantification of viral load (letter), 82
Vitamin A, in maternal morbidity in HIV-infected women, 37
Voluntary counseling, in prophylaxis for vertical HIV transmission, 369

Weck-Cell Ophthalmic Surgical Spears, for rectal secretion collection and analysis of mucosal HIV antibody, 297
Weight loss, enhanced oral ganciclovir systemic exposure with, 344
Women
  anal sex among HIV-seronegative, 393
  cell-free virus in breast milk of HIV-1-seropositive, 330
  intravaginal practices and vaginal and cervical mucosa of, 62
  readiness for HIV vaccine trials in, 451
  vitamin A effects on HIV-related morbidity in during pregnancy and postpartum, 37

Zidovudine
  congenital anomalies with prenatal use of, 249
  prenatal effect of on disease progression in perinatally HIV-1-infected infants, 154
  transplacental exposure of in fetal monkey brain mitochondria, 100
Zimbabwe, intravaginal practices and vaginal and cervical mucosa of women in, 62
Zolpidem, differential impairment of clearance, 129